SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA sign outside its office in Maryland
Regulatory
FDA Pushes Back PDUFA Dates for Amgen and Intercept
The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals’ Ocaliva for primary biliary cholangitis.
October 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Infant in the hospital wearing a ventila
RSV
Merck, Pfizer Tout Promising Respective Data in RSV With High Rates of Prevention
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory syncytial virus-associated infections in infants, while Pfizer’s RSV vaccine Abrysvo showed 90% effectiveness at preventing the most severe RSV cases in adults 60 years and older.
October 18, 2024
 · 
2 min read
 · 
Tristan Manalac
Drug Development
Kezar Cuts Lupus Program After Patient Deaths, Focuses on Autoimmune Hepatitis
Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed on an FDA clinical hold. Now, that program is being terminated.
October 17, 2024
 · 
2 min read
 · 
Annalee Armstrong
Hand holding pencil erasing an employee. Dismissal or bankrumptcy concept. Vector illustration.
Layoffs
Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D
As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.
October 17, 2024
 · 
2 min read
 · 
Angela Gabriel
Poznan, Poland – October 29, 2020: The Glaxosmithkline headquarters office building in Poznan. LOGO. GaxoSmithKline also called GSK is a British pharmaceutical company.
Infectious disease
GSK, ViiV Tout 99% Effectiveness for Long-Acting HIV PrEP as Gilead Gains Ground
Real-world evidence show that GSK and ViiV Healthcare’s long-acting pre-exposure prophylaxis Apretude can prevent nearly all HIV infections, while rival Gilead Sciences is moving quickly toward an approval for a twice-yearly option.
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Bavarian Nordic's sign outside its facility in Germany
Vaccines
Bavarian Nordic’s Jynneos Elicits ‘Robust’ Mpox Antibody Response in Adolescents: Study
The mpox vaccine induced an antibody response in adolescents aged 12 to 17 years that matched that in adults, suggesting the shot can be used to protect the highly susceptible group.
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: BMS sign on a building in San Diego, California/iStock, JHVEPhoto
Lymphoma
BMS’ Opdivo Bests Pfizer’s Adcetris in Late-Stage Hodgkin’s Lymphoma Study
Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a Phase III study that combined either therapy with doxorubicin, vinblastine and dacarbazine.
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Sanofi's Distribution Center in Quebec, Canada
Radiopharmaceuticals
Sanofi Inks $326M Radiopharma Deal With Orano
Thursday’s agreement with Orano Med is the second in as many months. Sanofi in September made its first foray into the radioligand space with a $110 million licensing deal with Orano Med and Texas biotech RadioMedix.
October 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Illustration of person on diverging path
Career Advice
Back to School? From Industry to Academia
In a tough labor market where layoffs continue, some are considering—or even moving—from industry to academia, according to a BioSpace poll. A career coach, scientist and general practitioner turned research coordinator share their thoughts.
October 17, 2024
 · 
6 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS